Scott Giacobello Sells 141,600 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CFO Scott Giacobello sold 141,600 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $4.13, for a total transaction of $584,808.00. Following the completion of the transaction, the chief financial officer owned 295,224 shares of the company’s stock, valued at approximately $1,219,275.12. This trade represents a 32.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Whitehawk Therapeutics Stock Performance

Shares of NASDAQ:WHWK traded down $0.12 during trading on Friday, hitting $4.11. The company’s stock had a trading volume of 571,343 shares, compared to its average volume of 169,490. The business has a 50 day moving average price of $3.43 and a two-hundred day moving average price of $2.77. The company has a market capitalization of $193.99 million, a PE ratio of 8.74 and a beta of 0.57. Whitehawk Therapeutics, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of WHWK. Orbimed Advisors LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at $7,915,000. Suvretta Capital Management LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at $7,030,000. Acuta Capital Partners LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at $6,480,000. Avoro Capital Advisors LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at $5,414,000. Finally, KVP Capital Advisors LP purchased a new stake in Whitehawk Therapeutics in the fourth quarter valued at $5,242,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on WHWK. Citigroup began coverage on shares of Whitehawk Therapeutics in a research report on Thursday. They set an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. JonesTrading began coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective for the company. Oppenheimer began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, Wall Street Zen cut shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.00.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.